All stock lists
Unlock the score
City Therapeutics, Inc. (NASDAQ:CTY)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
20.79+0.02 (+0.10%)
Insider Score
/ 100
CTY Insider Score
CITY THERAPEUTICS, INC. has a live Insider Score.
Scored on 1 qualifying trade from 1 insider in the last 90 days.
Financial Health Score
Sound
From CTY’s reported statements · Q2 2020 (trailing 12 months) · 4 of 5 pillars
Profitability20 / 20
Keeps a healthy share of every dollar it sells.
- Revenue
- $6.49B
- Net income
- $1.80B
- Net margin
- 27.7%
Leverage14 / 20
A manageable debt load.
- Total debt
- $4.66B
- Cash
- $5.0M
- Net debt / EBITDA
- 1.30x
Liquidity0 / 20
Owes more within a year than it holds to pay it.
- Current assets
- $1.04B
- Current liabilities
- $2.39B
- Current ratio
- 0.44
Cash generation20 / 20
The business funds itself from operations.
- Operating cash flow
- $3.31B
- Free cash flow
- $2.17B
- FCF margin
- 33.4%
Dilution & runway—
Share count history not available.
- Shares outstanding
- 0.0M
- Share growth (1y)
- —
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
CTY Income Statement
| Fiscal Period | Q2 2020 | Q1 2020 | Q4 2019 | Q3 2019 | Q2 2019 | Q1 2019 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 |
| Revenue | 524.00 M | 1.92 B | 2.01 B | 2.04 B | 2.05 B | 2.06 B |
| Revenue Growth (YoY) | -74.45 % | -6.67 % | -4.78 % | -5.12 % | -2.38 % | -3.52 % |
| Cost of Revenue | 490.00 M | 473.00 M | 613.00 M | 630.00 M | 588.00 M | 607.00 M |
| Gross Profit | 34.00 M | 1.45 B | 1.40 B | 1.41 B | 1.46 B | 1.45 B |
| SG&A Expense | 139.00 M | 143.00 M | -3.23 B | 1.29 B | 1.30 B | 1.29 B |
| R&D Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 139.00 M | 143.00 M | -3.23 B | 1.29 B | 1.30 B | 1.29 B |
| Operating Income | 679.00 M | 779.00 M | 626.00 M | 748.00 M | 750.00 M | 760.00 M |
| Pretax Income | 583.00 M | 680.00 M | 523.00 M | 643.00 M | 644.00 M | 658.00 M |
| Tax Provision | 153.00 M | 177.00 M | 137.00 M | 166.00 M | 167.00 M | 171.00 M |
| Net Income | 430.00 M | 503.00 M | 386.00 M | 477.00 M | 477.00 M | 487.00 M |
| EPS (Basic) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS (Diluted) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.